Navigation Links
BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza
Date:10/27/2008

Management to Host Conference Call at 8:30 a.m. Eastern Time Today to

Discuss Results

BIRMINGHAM, Ala., Oct. 27 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced results of an exploratory Phase 2 trial of intravenous (i.v.) peramivir, a neuraminidase inhibitor, in patients hospitalized for acute serious or potentially life-threatening influenza. The Phase 2 trial compared the efficacy and safety of five days of therapy with either 200 mg i.v. peramivir per day, 400 mg i.v. peramivir per day or 75 mg oral oseltamivir twice a day, in patients who required hospitalization related to influenza. These results will be submitted to an upcoming medical meeting.

The primary objective of the study was to evaluate time to clinical stability, which is a composite endpoint comprised of normalization of temperature, oxygen saturation, respiratory rate, systolic blood pressure and heart rate. This type of endpoint has previously been used in pneumonia studies, but not in influenza. Secondary objectives of the study included evaluation of viral shedding, mortality, clinical relapse and time to resumption of usual activities.

In the primary efficacy population, for all groups combined, the study demonstrated a median of 25.3 hours to clinical stability, a median of 2.0 log reduction in time weighted change from baseline in viral titer, zero mortality, no clinical relapse and a median of 10.8 days of time to resumption of usual activities. There were no statistically significant differences in any of the efficacy endpoints between the three treatment arms. Peramivir was generally safe and well-tolerated at these dose levels.

"This landmark study provides us gre
'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference
2. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
3. BioCryst to Present at UBS 2007 Global Life Sciences Conference
4. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
5. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
6. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
7. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
8. William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
9. BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008
10. BioCryst to Present at UBS 2008 Global Life Sciences Conference
11. BioCryst to Present at the JMP Healthcare Focus Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... BOSTON , Jan. 22, 2015  Transwestern | RBJ today ... feet of office space for Shire a leading biopharmaceutical company, ... . Transwestern | RBJ,s Robert Richards , president, and ... the lease for the entire five-floor building at 95 Hayden ...
(Date:1/22/2015)... RI (PRWEB) January 22, 2015 Protocol ... , The growing team of brand-neutral, independent consultants, Protocol ... Philip Rogers explained that over the years, his company ... , Moroso, Town of Plainfield, as well as others. ...
(Date:1/22/2015)... MA (PRWEB) January 22, 2015 zFlo ... is pleased to announce an exciting product from a new ... motion analysis solutions over the past 15 years, with offerings ... Most recently, their 3D IMU system (inertial measurement unit), iSen, ...
(Date:1/22/2015)... 2015 Selexis SA, a serial innovation ... Banks (RCBs) used for drug discovery to commercial manufacturing, ... include Next-Generation Sequencing (NGS) data packages. The ... manufacturing by ensuring the integrity of the gene, validation ...
Breaking Biology Technology:Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Protocol Networks Brings Independent Technology Consulting to the Constitution State 23D Motion Capture Just Got Easy 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2
... caprotec bioanalytics GmbH, a privately held ... (CCMS) platform technology for the analysis of small molecule ... EUR 1 million ($1.4 M) to its Series B ... 5 million ($7.2 M). The capital increase was fully ...
... Laboratories is pleased to announce that it has been ... represent the United Kingdom in the prestigious 2011 awards programme. ... of 25 Country Representatives and will now compete for a ... recognition of Trimega,s pioneering use of dual testing of hair ...
... Cord Blood America, Inc . (OTC BB: CBAI, CBAID) ... by 80 percent of its shareholders voting in a recent proxy ... 2011. The one for one hundred reverse split reduces ... shares. A "D" will be placed on the ticker ...
Cached Biology Technology:caprotec bioanalytics Increases Series B Financing in Second Closing to EUR 5 Million 2Trimega Laboratories Honoured to Represent UK at the European Business Awards 2Trimega Laboratories Honoured to Represent UK at the European Business Awards 3
(Date:1/22/2015)... Jan. 22, 2015 Research and Markets ... the "Global Wearable Technologies Market and Applications, ... Trends and Forecast 2014-2020" report to their ... smart devices that can be worn on the ...
(Date:12/22/2014)... Inc. (NASDAQ: NXTD and NXTDW) ("NXT-ID" or ... mobile commerce market, announces it has retained famous pickpocket, entertainer ... International CES debut of the Wocket™ biometric smart wallet.  ... NXT-ID booth January 6th and 7 th , 2015, demonstrating ...
(Date:12/19/2014)... DUBLIN , Dec. 18, 2014 Research and Markets ... "Micro Market Monitor: North America Perimeter Security Systems Market" ... http://photos.prnewswire.com/prnh/20130307/600769 The North American perimeter security market ... 2014 to 2019. Although the U.S. market holds a larger ...
Breaking Biology News(10 mins):Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3
... short- and long-term fisheries benefits could have prevented the ... is the last best chance for tuna, says University ... must act as if future generations of people are ... says Sumaila, who is presenting his findings with UBC ...
... Climate change is rapidly transforming the worlds oceans ... altering atmospheric and oceanic circulation, reported a panel of ... Advancement of Science (AAAS) annual meeting in Boston. ... sense of complacency about potential impacts from global climate ...
... , Sharks are disappearing from the worlds oceans. The numbers ... half due to increased demand for shark fins and meat, ... where millions of sharks are taken as bycatch each year. ... assessed by the World Conservation Union (IUCN), which is widely ...
Cached Biology News:UBC scientist invokes future generations to save tuna populations from collapse 2Climate change has major impact on oceans 2Climate change has major impact on oceans 3Climate change has major impact on oceans 4Ocean's fiercest predators now vulnerable to extinction 2
... nmol (individual) with sequence siTrio siRNA ... to your target gene of interestis our most ... more than 75% knockdown of your target gene ... for transfection and confirmation of optimal transfection with ...
... cocktail of 3 siRNAs specifically targeted to ... popular product. The siTrio reagent guarantees you ... target gene when used under standard conditions ... of optimal transfection with one of B-Bridges ...
... Vitamin D kit is an enzymeimmunoassay ... 25-hydroxyvitamin D (25-OH D) and other ... plasma. Our patented DIRECT assay technology ... and centrifugation and therefore facilitates automation ...
... is a complete assay system for the ... human serum or plasma. The assay incorporates ... the IDS 1,25D RIA followed by quantitation ... ready to use reagents, no organic or ...
Biology Products: